Logo image of ALDMS.PA

DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) Stock Fundamental Analysis

EPA:ALDMS - Euronext Paris - Matif - FR0012202497 - Common Stock - Currency: EUR

1.33  -0.02 (-1.48%)

Fundamental Rating

3

Taking everything into account, ALDMS scores 3 out of 10 in our fundamental rating. ALDMS was compared to 55 industry peers in the Health Care Equipment & Supplies industry. ALDMS has a bad profitability rating. Also its financial health evaluation is rather negative. ALDMS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALDMS has reported negative net income.
In the past year ALDMS had a positive cash flow from operations.
In the past 5 years ALDMS always reported negative net income.
In multiple years ALDMS reported negative operating cash flow during the last 5 years.
ALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

1.2 Ratios

ALDMS has a Return On Assets of -5.34%. This is in the lower half of the industry: ALDMS underperforms 63.64% of its industry peers.
ALDMS has a Return On Equity of -22.44%. This is in the lower half of the industry: ALDMS underperforms 67.27% of its industry peers.
Industry RankSector Rank
ROA -5.34%
ROE -22.44%
ROIC N/A
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ALDMS.PA Yearly ROA, ROE, ROICALDMS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

ALDMS's Gross Margin of 39.92% is on the low side compared to the rest of the industry. ALDMS is outperformed by 74.55% of its industry peers.
ALDMS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ALDMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
ALDMS.PA Yearly Profit, Operating, Gross MarginsALDMS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

ALDMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALDMS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALDMS has more shares outstanding
ALDMS has a better debt/assets ratio than last year.
ALDMS.PA Yearly Shares OutstandingALDMS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ALDMS.PA Yearly Total Debt VS Total AssetsALDMS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of 0.95, we must say that ALDMS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.95, ALDMS is not doing good in the industry: 65.45% of the companies in the same industry are doing better.
The Debt to FCF ratio of ALDMS is 5.57, which is a neutral value as it means it would take ALDMS, 5.57 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ALDMS (5.57) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.90 indicates that ALDMS is somewhat dependend on debt financing.
ALDMS has a worse Debt to Equity ratio (0.90) than 78.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.57
Altman-Z 0.95
ROIC/WACCN/A
WACC6.79%
ALDMS.PA Yearly LT Debt VS Equity VS FCFALDMS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 1.29 indicates that ALDMS should not have too much problems paying its short term obligations.
The Current ratio of ALDMS (1.29) is worse than 63.64% of its industry peers.
A Quick Ratio of 0.67 indicates that ALDMS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.67, ALDMS is doing worse than 74.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 0.67
ALDMS.PA Yearly Current Assets VS Current LiabilitesALDMS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

ALDMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
The Revenue has grown by 9.29% in the past year. This is quite good.
Measured over the past years, ALDMS shows a quite strong growth in Revenue. The Revenue has been growing by 8.24% on average per year.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87%
Revenue 1Y (TTM)9.29%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%8.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
ALDMS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.82% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.4%
Revenue Next 2Y13.86%
Revenue Next 3Y11.55%
Revenue Next 5Y12.82%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALDMS.PA Yearly Revenue VS EstimatesALDMS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
ALDMS.PA Yearly EPS VS EstimatesALDMS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2025 2026 2027 0 0.05 -0.05 0.1 -0.1 -0.15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALDMS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 12.91, ALDMS is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALDMS indicates a rather cheap valuation: ALDMS is cheaper than 83.64% of the companies listed in the same industry.
ALDMS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.44.
Industry RankSector Rank
PE N/A
Fwd PE 12.91
ALDMS.PA Price Earnings VS Forward Price EarningsALDMS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ALDMS is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.7
EV/EBITDA N/A
ALDMS.PA Per share dataALDMS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALDMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIAGNOSTIC MEDICAL SYSTEMS

EPA:ALDMS (7/21/2025, 7:00:00 PM)

1.33

-0.02 (-1.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.23%
Ins Owner ChangeN/A
Market Cap27.73M
Analysts86
Price Target1.99 (49.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.33%
PT rev (3m)8.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 12.91
P/S 0.6
P/FCF 7.7
P/OCF 7.7
P/B 2.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)0.1
Fwd EY7.74%
FCF(TTM)0.17
FCFY12.99%
OCF(TTM)0.17
OCFY12.99%
SpS2.21
BVpS0.62
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.34%
ROE -22.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.92%
FCFM 7.82%
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
F-Score6
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.57
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 0.67
Altman-Z 0.95
F-Score6
WACC6.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.29%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%8.7%
Revenue Next Year19.4%
Revenue Next 2Y13.86%
Revenue Next 3Y11.55%
Revenue Next 5Y12.82%
EBIT growth 1Y35.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1225%
EBIT Next 3Y158.38%
EBIT Next 5Y101.41%
FCF growth 1Y318.91%
FCF growth 3YN/A
FCF growth 5Y58.15%
OCF growth 1Y318.91%
OCF growth 3YN/A
OCF growth 5Y58.15%